Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo
Findings seen in patients with ischemic stroke without occlusion of large or medium-sized vessels, at least one moderately to severely weak limb
Myocardial infarction not associated with decrease in global cognition, memory, executive function